A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose

Haemophilia

Volumn 14, Issue 2, 2008, Pages 281-286

  Rubinger, Morel ^a,f   Lillicrap, D ^b   Rivard, G E ^c   Teitel, J ^d   Carcao, M ^d   Hensman, C ^b   Walker, I ^e  

^a UNIVERSITY OF MANITOBA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^f CANCERCARE MANITOBA   (Canada)

Author keywords

Factor VIII; Haemophilia; Inhibitor; Surveillance

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; SUCROSE;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CANADA; CHILD; CLINICAL TRIAL; DRUG FORMULATION; HEMOPHILIA A; HUMAN; IMMUNOASSAY; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 40349088971     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01634.x     Document Type: Article

References (23)